144 related articles for article (PubMed ID: 212377)
1. Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
Fresen KO; Cho MS; zur Hausen H
Int J Cancer; 1978 Oct; 22(4):378-83. PubMed ID: 212377
[TBL] [Abstract][Full Text] [Related]
2. NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV.
Fresen KO; Cho MS; Gissmann L; zur Hausen H
Intervirology; 1980; 12(6):303-10. PubMed ID: 6244234
[TBL] [Abstract][Full Text] [Related]
3. Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
Cho MS; Fresen KO; zur Hausen H
Int J Cancer; 1980 Sep; 26(3):357-63. PubMed ID: 6270006
[TBL] [Abstract][Full Text] [Related]
4. Somatic cell hybrids between human lymphoma cell lines. V. IdUrd inducibility and P3HR-1 superinfectability of Daudi/HeLa (DAD) and Daudi/P3HR-1 (DIP-1) cell lines.
Moar MH; Ber R; Klein G; Westman A; Eriksson I
Int J Cancer; 1978 Dec; 22(6):669-74. PubMed ID: 82545
[TBL] [Abstract][Full Text] [Related]
5. Productive Epstein-Barr viral infection of the human lymphoblastoid cell line 6410 with release of early antigen inducing and transforming virus.
Traul KA; Stephens R; Gerber P; Peterson WD
Int J Cancer; 1977 Aug; 20(2):247-55. PubMed ID: 197026
[TBL] [Abstract][Full Text] [Related]
6. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of Epstein-Barr virus induction by the amino acid analogue, L-canavanine.
Yamamoto N; Mueller-Lantzsch N; zur Hausen H
Int J Cancer; 1980 Apr; 25(4):439-43. PubMed ID: 6246007
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.
Sairenji T; Hinuma Y
Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005
[TBL] [Abstract][Full Text] [Related]
9. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
[TBL] [Abstract][Full Text] [Related]
10. Attempts to induce interferon production by IdUrd induction and EBV superinfection in human lymphoma lines and their hybrids.
Klein G; Vilcek J
J Gen Virol; 1980 Jan; 46(1):111-7. PubMed ID: 6243338
[TBL] [Abstract][Full Text] [Related]
11. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle.
Klein G; Clements G; Zeuthen J; Westman A
Int J Cancer; 1976 Jun; 17(6):715-24. PubMed ID: 59708
[TBL] [Abstract][Full Text] [Related]
12. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
13. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
14. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
Klein G; Sugden B; Leibold W; Menezes J
Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
[TBL] [Abstract][Full Text] [Related]
15. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
Takimoto T; Sato H; Ogura H
Auris Nasus Larynx; 1986; 13(3):199-205. PubMed ID: 3036055
[TBL] [Abstract][Full Text] [Related]
16. Effect of adenine arabinoside on Epstein-Barr virus in vitro.
Coker-Vann M; Dolin R
J Infect Dis; 1977 Mar; 135(3):447-53. PubMed ID: 191542
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of D and R components of Epstein-Barr virus early antigen after superinfection and after induction with 5-iododeoxyuridine.
Simonová I; Závadová H; Vonka V
Acta Virol; 1977 May; 21(3):184-8. PubMed ID: 18915
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of TPA and n-butyrate on induction of Ii and EBV antigens in the P3HR-1 lymphoblastoid cell line.
Sairenji T; Spiro RC; Humphreys RE
Hematol Oncol; 1984; 2(4):381-9. PubMed ID: 6098544
[TBL] [Abstract][Full Text] [Related]
19. Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells.
Lin JC; Raab-Traub N
J Virol; 1987 Jun; 61(6):1985-91. PubMed ID: 3033325
[TBL] [Abstract][Full Text] [Related]
20. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Kurakata S; Ramos OF; Klein G; Klein E
Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
